此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Perioperative Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery (PROPHTAZ)

2026年9月29日 更新者:Central Hospital, Nancy, France

PROPHTAZ: Evaluation of Pharmacokinetic/Pharmacodynamic Target Attainment of Piperacillin During Major Hepatic and Pancreatic Surgery, a Prospective Observational Pharmacokinetic Study

Hepatic and pancreatic surgeries are associated with a high risk of surgical site infections, particularly in patients with preoperative biliary drainage, which is frequently associated with bacterial colonization of bile. In this context, perioperative antibiotic prophylaxis is essential, and recent guidelines recommend the use of piperacillin/tazobactam in selected high-risk patients.

However, piperacillin, like other β-lactam antibiotics, exhibits pharmacokinetic variability that may be exacerbated during major surgery due to factors such as fluid shifts, hypoalbuminemia, and changes in volume of distribution. These alterations may result in suboptimal antibiotic exposure during the perioperative period, potentially compromising prophylactic efficacy.

Despite these concerns, standard dosing regimens remain unchanged across different types of major abdominal surgery, including hepatic and pancreatic procedures, which differ significantly in terms of duration, physiological impact, and intraoperative management.

The PROPHTAZ study is a prospective, single-center observational pharmacokinetic study designed to evaluate whether standard perioperative administration of piperacillin/tazobactam achieves predefined pharmacokinetic/pharmacodynamic (PK/PD) targets in patients undergoing hepatic or pancreatic surgery. The primary objective is to determine the proportion of patients achieving adequate PK/PD exposure during surgery. Secondary objectives include describing perioperative plasma concentrations, assessing pharmacokinetic variability, identifying factors associated with target non-attainment, and comparing outcomes between surgical subgroups.

This study aims to provide clinically relevant data to assess the adequacy of current prophylactic dosing strategies and to support potential optimization of antibiotic administration in high-risk surgical patients.

研究概览

地位

招聘中

研究类型

观察性的

注册 (估计的)

60

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

      • Nancy、法国
        • 招聘中
        • CHRU de NANCY
    • Lorraine
      • Vandœuvre-lès-Nancy、Lorraine、法国、54500
        • 尚未招聘
        • CHRU de Nancy
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population consists of adult patients undergoing elective hepatic or pancreatic surgery at a tertiary care university hospital (CHRU Nancy, France). Eligible patients are those receiving perioperative antibiotic prophylaxis with piperacillin/tazobactam according to current clinical guidelines, particularly in the context of preoperative biliary drainage or high risk of biliary contamination.

These patients represent a high-risk surgical population for surgical site infections, characterized by complex procedures, potential intraoperative hemodynamic variations, and significant pharmacokinetic variability. Patients are managed in a perioperative setting including the operating room and postoperative admission to a surgical intensive care or intermediate care unit.

描述

Inclusion Criteria:

  • Adults > or = to 18 years old
  • Scheduled for major hepatic or pancreatic surgery
  • Receiving piperacillin/tazobactam as perioperative antibiotic prophylaxis according to guidelines

Exclusion Criteria:

  • decline to participate
  • Known allergy of beta-lactam

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Adult patients with scheduled pancreatic or major hepatic surgery

Adult patients with scheduled pancreatic surgery or major hepatic receiving piperacillin/tazobactam as antibiotic prophylaxis

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
PK/PD target attainment of piperacillin
大体时间:4 hours after the administration of piperacillin

Proportion of patients achieving the predefined* PK/PD target during the perioperative period

*estimated free concentration of piperacillin (80% of the total concentration) above the MIC of the isolated pathogen from bile samples throughout the surgical procedure (from incision to wound closure)

4 hours after the administration of piperacillin

次要结果测量

结果测量
措施说明
大体时间
Plasma piperacillin concentration
大体时间:4 hours after the administration of piperacillin

Total (measured) et free (estimated) concentration of piperacilline throughout at two timepoints: surgical incision and wound closure

4 hours after the administration of piperacillin
Factors associated with target attainment
大体时间:4 hours after the administration of piperacillin

Analysis of clinical and biological covariates associated with pharmacokinetic variability and the achievement of pharmacodynamic targets

4 hours after the administration of piperacillin

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月25日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年5月1日

研究注册日期

首次提交

2026年4月9日

首先提交符合 QC 标准的

2026年4月27日

首次发布 (实际的)

2026年4月30日

研究记录更新

最后更新发布 (实际的)

2026年10月2日

上次提交的符合 QC 标准的更新

2026年9月29日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅